Issue navigation
Volume 25, Issue Supplement_1, June 2023
Abstracts from the 2023 Pediatric Neuro-Oncology Research Conference
FINAL CATEGORY: HIGH GRADE GLIOMA/GLIOMATOSIS CEREBRI - HGG (continued)
HGG-02. METABOLIC TARGETING OF HIGH-GRADE GLIOMAS WITH MTAP LOSS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i38, https://doi.org/10.1093/neuonc/noad073.151
HGG-03. HIGH-GRADE GLIOMA IN YOUNG CHILDREN IS HISTOLOGICALLY, MOLECULARLY, AND CLINICALLY DIVERSE—RESULTS FROM THE SJYC07 TRIAL AND INSTITUTIONAL EXPERIENCE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i38–i39, https://doi.org/10.1093/neuonc/noad073.152
HGG-04. INFANTILE HIGH GRADE GLIOMA: HONG KONG EXPERIENCE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i39, https://doi.org/10.1093/neuonc/noad073.153
HGG-05. PERTURBING GABAERGIC NEURONAL LINEAGE IN DIFFUSE HEMISPHERIC GLIOMA, H3G34-MUTANT, HIGHLIGHTS CDK6 AS A CLINICALLY ACTIONABLE TARGET
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i39, https://doi.org/10.1093/neuonc/noad073.154
HGG-06. CHARACTERIZATION OF THE EFFECT OF THE ORAL IRON-MIMETIC GALLIUM MALTOLATE ON PEDIATRIC GLIOBLASTOMA GROWTH IN VIVO
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i39, https://doi.org/10.1093/neuonc/noad073.155
HGG-07. OVEREXPRESSION OF A PLAG-FAMILY TRANSCRIPTION FACTOR DURING MURINE BRAIN DEVELOPMENT CAUSES BRAIN TUMOR FORMATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i39–i40, https://doi.org/10.1093/neuonc/noad073.156
HGG-08. COMBINATORIAL ACTIVITY OF CDK4/6-INHIBITORS AND TRAMETINIB IN PEDIATRIC HIGH-GRADE GLIOMA WITH BRAFV600E MUTATION AND HOMOZYGOUS CDKN2A DELETION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i40, https://doi.org/10.1093/neuonc/noad073.157
HGG-09. GLIOMATOSIS CEREBRI IN CHILDREN: A POOR PROGNOSTIC, HIGHLY INFILTRATIVE PHENOTYPE OF DIFFUSE PEDIATRIC HIGH-GRADE GLIOMAS WITH DISTINCT MOLECULAR FEATURES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i40–i41, https://doi.org/10.1093/neuonc/noad073.158
HGG-10. A SAFETY AND EFFICACY STUDY OF NOVOTTF-100A FOR PEDIATRIC HIGH-GRADE GLIOMA: RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE FIRST THREE CASES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i41, https://doi.org/10.1093/neuonc/noad073.159
HGG-11. APPLICATION OF SHUNT IN PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMA COMPLICATED WITH HYDROCEPHALUS: A 10-YEAR EXPERIENCE FROM A SINGLE CENTER
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i41, https://doi.org/10.1093/neuonc/noad073.160
HGG-12. INFANT HEMISPHERIC GLIOMA: CLINICAL AND MOLECULAR CHARACTERISTICS AND RESULTS OF TARGETED THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i41, https://doi.org/10.1093/neuonc/noad073.161
HGG-13. ONCOGENIC STAT3 AND SHP2 ACTIVATION IN ROS1-FUSION DRIVEN INFANT-TYPE HEMISPHERIC GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i42, https://doi.org/10.1093/neuonc/noad073.162
HGG-14. RAS PATHWAY MEDIATED REGULATION OF HISTONE METHYLTRANSFERASE AND TUMOR SUPPRESSOR SETD2 IN PEDIATRIC HIGH GRADE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i42, https://doi.org/10.1093/neuonc/noad073.163
HGG-15. HIGH-GRADE GLIOMAS OCCURRING IN TEENAGERS AND YOUNG ADULT PATIENTS COMPRISE NOVEL MOLECULAR SUBGROUPS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i42, https://doi.org/10.1093/neuonc/noad073.164
HGG-16. COMPARATIVE ANALYSIS OF AUTOPHAGY IN DRUG RESPONSES AND AGGRESSIVE BEHAVIOR OF ADULT VERSUS PEDIATRIC GLIOMA CELL LINES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i42, https://doi.org/10.1093/neuonc/noad073.165
HGG-17. SINGLE-CELL AND SPATIAL ANALYSES DECIPHER THE UNIQUE INVASIVE GROWTH PATTERN OF GLIOMATOSIS CEREBRI
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i42–i43, https://doi.org/10.1093/neuonc/noad073.166
HGG-18. SINGLE CELL RNA-SEQ ANALYSIS OF PEDIATRIC HIGH-GRADE GLIOMA PATIENT SAMPLES IDENTIFIES COMMON GLIAL AND IMMUNE CELL TYPES THAT HELP TO EXPLAIN HETEROGENEITY AND TUMORIGENESIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i43, https://doi.org/10.1093/neuonc/noad073.167
HGG-19. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i43–i44, https://doi.org/10.1093/neuonc/noad073.168
HGG-20. NOVEL PAEDIATRIC CASE OF A SPINAL HIGH-GRADE ASTROCYTOMA WITH PILOID FEATURES IN A PATIENT WITH NOONAN SYNDROME
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i44, https://doi.org/10.1093/neuonc/noad073.169
HGG-21. ABERRANT SPLICING OF CLK1 IN PEDIATRIC HIGH-GRADE GLIOMAS DISRUPTS KEY ONCOGENIC TRANSCRIPTIONAL PROGRAMS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i44, https://doi.org/10.1093/neuonc/noad073.170
HGG-22. PROGNOSTIC FACTORS FOR PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH NON-DIPG GRADE 4 GLIOMAS: A CONTEMPORARY POOLED INSTITUTIONAL EXPERIENCE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i44, https://doi.org/10.1093/neuonc/noad073.171
HGG-23. DECIPHERING THE RELATIONSHIP OF MICROSATELLITE-INSTABILITY AND MUTATIONAL BURDEN IN HIGH-GRADE GLIOMA PATIENTS WITH CONSTITUTIONALLY IMPAIRED DNA DAMAGE RESPONSE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i44–i45, https://doi.org/10.1093/neuonc/noad073.172
HGG-24. A NOVEL ONCOGENIC ROLE FOR MENIN IN GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i45, https://doi.org/10.1093/neuonc/noad073.173
HGG-25. TARGETED DRUGS SYNERGIZE WITH DOUBLE ALKYLATOR THERAPY IN H3.3 G34R/V PEDIATRIC HIGH-GRADE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i45, https://doi.org/10.1093/neuonc/noad073.174
HGG-26. GENOMIC AND IMMUNE ANALYSIS OF PRIMARY REPLICATION-REPAIR DEFICIENT (RRD) GLIOMAS REVEALS THREE SUBGROUPS WITH DISTINCT DRIVERS AND RESPONSE TO IMMUNOTHERAPY: AN IRRDC REPORT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i45, https://doi.org/10.1093/neuonc/noad073.175
HGG-27. THE IMPACT OF MISMATCH REPAIR DEFICIENCY ON GLIOMAS IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS; A REPORT FROM THE IRRDC AND THE GLIOMA TASK FORCE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i45–i46, https://doi.org/10.1093/neuonc/noad073.176
HGG-28. INTERIM ANALYSIS OF THE GCC1949 PHASE 2 TRIAL USING INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i46, https://doi.org/10.1093/neuonc/noad073.177
FINAL CATEGORY: IMAGING - IMG
IMG-01. LONGITUDINAL FMRI OF VISUAL, AUDITORY AND MOTOR FUNCTION IN PEDIATRIC CRANIOPHARYNGIOMA AFTER TREATMENT WITH PROTON RADIOTHERAPY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i46, https://doi.org/10.1093/neuonc/noad073.178
IMG-02. VISUALIZATION OF TIGIT IN THE GLIOMA MICROENVIRONMENT: THE CREATION OF A PET IMAGING TRACER
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i46–i47, https://doi.org/10.1093/neuonc/noad073.179
IMG-03. HARNESSING COMPUTATIONAL IMAGING, SCALABLE CLOUD-BASED WORKFLOWS, AND MULTI-MODAL DATA ANALYTICS WITH INTEROPERABLE SOFTWARE PLATFORMS IN PEDIATRIC NEURO-ONCOLOGY; THE ROAD AHEAD FOR CHILDREN’S BRAIN TUMOR NETWORK (CBTN)
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i47, https://doi.org/10.1093/neuonc/noad073.180
IMG-04. POTENTIAL TARGETS FOR THERANOSTICS IN PEDIATRIC HIGH-GRADE CENTRAL NERVOUS SYSTEM (CNS) TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i47, https://doi.org/10.1093/neuonc/noad073.181
IMG-05. A MULTI-INSTITUTIONAL AND MULTI-HISTOLOGY PEDIATRIC-SPECIFIC BRAIN TUMOR SUBREGION SEGMENTATION TOOL: FACILITATING RAPNO-BASED ASSESSMENT OF TREATMENT RESPONSE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i47, https://doi.org/10.1093/neuonc/noad073.182
IMG-06. RADIOMIC-BASED RISK STRATIFICATION OF PEDIATRIC LOW-GRADE GLIOMA REVEALS DIFFERENTIALLY EXPRESSED MOLECULAR PROCESSES CONTRIBUTING TO VARIABLE PATIENT PROGNOSIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i47–i48, https://doi.org/10.1093/neuonc/noad073.183
IMG-07. MOLECULAR PROCESSES GIVE RISE TO EMERGENCE OF RADIO-PHENOTYPES ON MRI SCANS OF PEDIATRIC LOW-GRADE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i48, https://doi.org/10.1093/neuonc/noad073.184
IMG-08. VOLUMETRIC MEASUREMENT OF TUMOR SIZE OUTPERFORMS STANDARD TWO-DIMENSIONAL METHOD IN EARLY PREDICTION OF TUMOR PROGRESSION IN PEDIATRIC GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i48, https://doi.org/10.1093/neuonc/noad073.185
IMG-09. DETERMINING OPTIMAL IMAGING SCHEDULE FOR PLGG AND PHGG PATIENTS OFF-THERAPY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i48, https://doi.org/10.1093/neuonc/noad073.186
IMG-10. MAGNETIC RESONANCE FUNCTIONAL IMAGING BIOMARKER FOR DISTINGUISHING HIGH GRADE FROM LOW GRADE PEDIATRIC BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i48–i49, https://doi.org/10.1093/neuonc/noad073.187
FINAL CATEGORY: IMMUNOLOGY/IMMUNOTHERAPY - IMMU
IMMU-01. EVALUATING THE IMPACT OF CAR DESIGN ON THE TUMOR IMMUNE MICROENVIRONMENT AND ANTI-TUMOR RESPONSE IN SYNGENEIC GLIOMA MODELS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i49, https://doi.org/10.1093/neuonc/noad073.188
IMMU-02. CMV-EXPANDED T-CELLS IN GLIOBLASTOMA PATIENTS: TRANSLATIONAL RESEARCH
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i49, https://doi.org/10.1093/neuonc/noad073.189
IMMU-03. IDENTIFICATION OF GENETIC BIOMARKERS TO PREDICT RESPONSE TO HSV-1 G207 AND POLIO:RHINOVIRUS IMMUNOTHERAPY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i49, https://doi.org/10.1093/neuonc/noad073.190
IMMU-04. TARGETING ALTERNATIVE SPLICING VARIANTS TO STIMULATE ANTI-TUMOR IMMUNITY IN A NOVEL SYNGENEIC MOUSE MODEL OF DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i49–i50, https://doi.org/10.1093/neuonc/noad073.191
IMMU-05. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i50, https://doi.org/10.1093/neuonc/noad073.192
IMMU-06. SYSTEMIC MRNA VACCINES RESET IMMUNOGENICITY AGAINST DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i50, https://doi.org/10.1093/neuonc/noad073.193
IMMU-07. TACEDINALINE (CI994), A CLASS I HDAC INHIBITOR, TARGETS INTRINSIC TUMOR GROWTH AND LEPTOMENINGEAL DISSEMINATION IN MYC-DRIVEN MEDULLOBLASTOMA WHILE MAKING THEM SUSCEPTIBLE TO ANTI-CD47 INDUCED MACROPHAGE PHAGOCYTOSIS VIA NF-KB-TGM2 DRIVEN TUMOR INFLAMMATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i50, https://doi.org/10.1093/neuonc/noad073.194
IMMU-08. SALVAGE IMMUNOTHERAPIES FOR REPLICATION REPAIR DEFICIENT (RRD) HIGH-GRADE GLIOMA FAILING ANTI-PD1 MONOTHERAPY: AN IRRDC REPORT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i50–i51, https://doi.org/10.1093/neuonc/noad073.195
IMMU-09. DISSECTING THE INTERPLAY BETWEEN THE ENDOGENOUS IMMUNE RESPONSE AND ONCOLYTIC VIRUS THERAPY IN PEDIATRIC BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i51, https://doi.org/10.1093/neuonc/noad073.196
IMMU-10. PILOCYTIC ASTROCYTOMAS SHOW EVIDENCE OF INTRINSIC IMMUNE SURVEILLANCE AND ACTIVATION WITHIN THE TUMOR MICROENVIRONMENT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i51, https://doi.org/10.1093/neuonc/noad073.197
IMMU-11. PRECLINICAL HIGH-RISK PEDIATRIC BRAIN TUMOR MODELS FOR IMMUNOTHERAPY: HURDLES AND THE WAY FORWARD
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i51–i52, https://doi.org/10.1093/neuonc/noad073.198
IMMU-12. T CELL SEQUESTRATION IN POSTERIOR FOSSA TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i52, https://doi.org/10.1093/neuonc/noad073.199
IMMU-13. PRECLINICAL EFFICACY OF MULTI-ANTIGEN (HER2/EGFR806/B7-H3/IL13RA2) TARGETING QUAD-CAR T CELLS AGAINST DIFFUSE MIDLINE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i52, https://doi.org/10.1093/neuonc/noad073.200
IMMU-14. WAKING THE SLEEPING GIANT: TLR7/8 AGONIST TREATMENT STIMULATES TUMOR-ASSOCIATED MYELOID CELLS FOR MEDULLOBLASTOMA IMMUNOTHERAPY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i52, https://doi.org/10.1093/neuonc/noad073.201
IMMU-15. PHASE I TRIAL OF GD2.CART-CELLS AUGMENTED WITH A CONSTITUTIVELY ACTIVE INTERLEUKIN-7 RECEPTOR (C7R) FOR TREATMENT OF HIGH-GRADE PEDIATRIC CNS TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i52–i53, https://doi.org/10.1093/neuonc/noad073.202
IMMU-16. IDENTIFICATION OF TUMOR REJECTION ANTIGENS FOR PRECISION ADOPTIVE CELLULAR THERAPY FOR PEDIATRIC GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i53, https://doi.org/10.1093/neuonc/noad073.203
IMMU-17. DEVELOPMENT OF AN INTRACRANIAL CANNULA IMPLANTATION SYSTEM FOR SERIAL LOCOREGIONAL CAR T CELL INFUSIONS IN MICE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i53, https://doi.org/10.1093/neuonc/noad073.204
IMMU-18. TARGETING GD2 IN THALAMIC DIFFUSE MIDLINE GLIOMA WITH TRANSIENT MRNA CAR T CELLS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i53, https://doi.org/10.1093/neuonc/noad073.205
IMMU-19. NIVOLUMAB-INDUCED CNS DEMYELINATION IN A 15-YEAR-OLD WITH CLASSIC HODGKIN LYMPHOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i53, https://doi.org/10.1093/neuonc/noad073.206
IMMU-20. EVALUATION OF B7-H3 NANOBODY CAR-T CELLS IN PEDIATRIC GLIOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i53–i54, https://doi.org/10.1093/neuonc/noad073.207
IMMU-21. ELUCIDATING THE CELLULAR MECHANISMS OF THERAPEUTIC BENEFIT UNDERLYING ADOPTIVE CELLULAR THERAPY IN MODELS OF GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i54, https://doi.org/10.1093/neuonc/noad073.208
IMMU-22. ALLOGENEIC NK CELLS SECRETING IL15 AND RESISTANT TO TGF-β Show Antitumor Activity Against Gliobastoma
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i54, https://doi.org/10.1093/neuonc/noad073.209
IMMU-23. RESEARCH ON MULTI-ANTIGEN T CELL INFUSION AGAINST NEURO-ONCOLOGIC DISEASE (ReMIND)
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i54, https://doi.org/10.1093/neuonc/noad073.210
FINAL CATEGORY: LOW GRADE GLIOMAS - LGG
LGG-01. DEVELOPMENT OF A WEB-BASED CALCULATOR APPLICATION FOR PREDICTING SHORT- AND LONG-TERMSURVIVAL IN PEDIATRIC OPTIC PATHWAY GLIOMA: A POPULATION-BASED DATABASE ANALYSIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i54–i55, https://doi.org/10.1093/neuonc/noad073.211
LGG-02. DRUG-CLASS SPECIFIC GENE-BASED MAPK SENSITIVITY SCORES (MSS) PREDICT SENSITIVITY TO MAPK INHIBITORS AND IDENTIFY IMMUNE INFILTRATION AS PUTATIVE TARGET IN PEDIATRIC LOW-GRADE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i55, https://doi.org/10.1093/neuonc/noad073.212
LGG-03. EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i55, https://doi.org/10.1093/neuonc/noad073.213
LGG-04. CLINICALLY RELEVANT MODELING OF FUSION-DRIVEN PEDIATRIC LOW GRADE GLIOMAS USING DROSOPHILA MELANOGASTER
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i55–i56, https://doi.org/10.1093/neuonc/noad073.214
LGG-05. IMAGING-BASED DEEP LEARNING FOR EVENT-FREE SURVIVAL PREDICTION IN PATIENTS WITH PEDIATRIC LOW-GRADE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i56, https://doi.org/10.1093/neuonc/noad073.215
LGG-06. DEVELOPMENT OF A WEB-BASED MOBILE DEVICE CALCULATOR APPLICATION FOR PREDICTING SHORT- AND LONG-TERM SURVIVAL IN PEDIATRIC OPTIC PATHWAY GLIOMA: A POPULATION-BASED DATABASE ANALYSIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i56, https://doi.org/10.1093/neuonc/noad073.216
LGG-07. TARGETED THERAPY IN PEDIATRIC LOW-GRADE GLIOMAS; REAL WORLD DATA IN THE CONTEXT OF CONVENTIONAL TREATMENT MODALITIES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i56–i57, https://doi.org/10.1093/neuonc/noad073.217
LGG-08. TARGETED THERAPY IN BRAFV600E-DRIVEN PEDIATRIC GLIOMAS: UNCOVERING MECHANISMS OF RESISTANCE THROUGH A MULTI-OMIC APPROACH
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i57, https://doi.org/10.1093/neuonc/noad073.218
LGG-09. CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i57, https://doi.org/10.1093/neuonc/noad073.219
LGG-10. TREATMENT-RELATED MYELODYSPLASTIC SYNDROME FOLLOWING CHEMOTHERAPY FOR PEDIATRIC LOW-GRADE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i57, https://doi.org/10.1093/neuonc/noad073.220
LGG-11. COGNITIVE, ACADEMIC, AND QUALITY OF LIFE OUTCOMES IN SURVIVORS OF PEDIATRIC LOW-GRADE GLIOMA: CHALLENGING THE ‘BENIGN TUMOR’ PERCEPTION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i57–i58, https://doi.org/10.1093/neuonc/noad073.221
LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i58, https://doi.org/10.1093/neuonc/noad073.222
LGG-13. GANGLIOGLIOMA DEEP TRANSCRIPTOMICS REVEALS A CD34+ PRIMITIVE NEUROECTODERM NEURAL PRECURSOR-LIKE POPULATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i58, https://doi.org/10.1093/neuonc/noad073.223
LGG-14. TREATMENT OF TWO PEDIATRIC FGFR-ALTERED LOW-GRADE GLIONEURONAL TUMORS WITH MEK INHIBITION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i58, https://doi.org/10.1093/neuonc/noad073.224
LGG-15. SINGLE-NUCLEUS AND BULK RNA SEQUENCING OF PEDIATRIC PILOCYTIC ASTROCYTOMAS REVEALS CNS LOCATION-ASSOCIATED TUMOR CELL AND MICROENVIRONMENTAL HETEROGENEITY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i58–i59, https://doi.org/10.1093/neuonc/noad073.225
LGG-16. NOVEL COMBINATION THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMA AND CHARACTERIZATION OF THE UNDERLYING CELL DEATH MECHANISMS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i59, https://doi.org/10.1093/neuonc/noad073.226
LGG-17. EPIGENETICALLY DEFINED ANGIOCENTRIC GLIOMAS MAY LACK ANGIOCENTRIC GROWTH AND INSTEAD SHOW A VARIETY OF GROWTH PATTERNS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i59–i60, https://doi.org/10.1093/neuonc/noad073.227
LGG-19. MULTI-MODALITY CHARACTERIZATION OF PEDIATRIC LOW-GRADE GLIOMA: THE ADDED VALUE OF DIFFERENT DATA MODALITIES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i60, https://doi.org/10.1093/neuonc/noad073.228
LGG-20. LANDSCAPE OF FGFR ALTERATIONS IN PEDIATRIC AND AYA GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i60, https://doi.org/10.1093/neuonc/noad073.229
LGG-21. FGFR1 GENE MUTATION AS A POTENTIAL RISK FACTOR FOR SPONTANEOUS INTRACRANIAL HEMORRHAGE IN PEDIATRIC LOW GRADE GLIOMA PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i60, https://doi.org/10.1093/neuonc/noad073.230
LGG-22. CHARACTERIZATION OF THE TUMOR MICROENVIRONMENT IN PEDIATRIC LOW-GRADE GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i60–i61, https://doi.org/10.1093/neuonc/noad073.231
LGG-23. OUTCOMES UTILIZING BRAF INHIBITION MONOTHERAPY IN BRAFV600E MUTATED PEDIATRIC LOW GRADE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i61, https://doi.org/10.1093/neuonc/noad073.232
LGG-24. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR MANAGEMENT AND OUTCOME: A SINGLE CENTER EXPERIENCE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i61, https://doi.org/10.1093/neuonc/noad073.233
FINAL CATEGORY: MEDULLOBLASTOMAS - MDB
MDB-01. ELUCIDATING THE ROLE OF THE BAIAP2-CDC42 INTERACTION MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i61, https://doi.org/10.1093/neuonc/noad073.234
MDB-02. NUCLEAR ENVELOPE PHOSPHATASE CTDNEP1 MUTATIONS POTENTIATE AGGRESSIVE MEDULLOBLASTOMA BY TRIGGERING MYC ACTIVATION AND GENOMIC INSTABILITY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i61–i62, https://doi.org/10.1093/neuonc/noad073.235
MDB-03. DFMO AS A TREATMENT STRATEGY IN GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i62, https://doi.org/10.1093/neuonc/noad073.236
MDB-04. SINGLE-CELL TRANSCRIPTOMIC ANALYSIS REVEALS DISTINCT GENOMIC LANDSCAPES, CELL TRAJECTORIES, AND TUMOUR-MICROENVIRONMENT INTERACTIONS IN FOUR SUBTYPES OF MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i62, https://doi.org/10.1093/neuonc/noad073.237
MDB-05. HUMAN FETAL CEREBELLAR CELL ATLAS INFORMS MEDULLOBLASTOMA ORIGIN AND ONCOGENESIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i62, https://doi.org/10.1093/neuonc/noad073.238
MDB-06. PLASMA MEMBRANE PROFILING REVEALS A TARGETABLE CELL-SURFACE PHENOTYPE OF WNT-MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i62, https://doi.org/10.1093/neuonc/noad073.239
MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i62–i63, https://doi.org/10.1093/neuonc/noad073.240
MDB-08. THYROID HORMONES INHIBIT MEDULLOBLASTOMA PROGRESSION THROUGH INDUCING TUMOR CELL DIFFERENTIATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i63, https://doi.org/10.1093/neuonc/noad073.241
MDB-09. IMPACT OF PRDM6 ON CHROMATIN ACCESSIBILITY, GENE EXPRESSION, AND MEDULLOBLASTOMA FORMATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i63, https://doi.org/10.1093/neuonc/noad073.242
MDB-10. EPIDEMIOLOGICAL PROFILE OF MEDULLOBLASTOMA IN MOROCCO: A 2-YEAR RETROSPECTIVE STUDY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i63, https://doi.org/10.1093/neuonc/noad073.243
MDB-11. AN ONLINE CALCULATOR USING MACHINE LEARNING FOR PREDICTION OF SURVIVAL IN PEDIATRIC PATIENTS WITH MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i63–i64, https://doi.org/10.1093/neuonc/noad073.244
MDB-12. TRANS-SPECIES ANALYSIS OF REPLICATION-REPAIR DEFICIENT (RRD) MEDULLOBLASTOMA AND RESPONSE TO IMMUNE-CHECKPOINT INHIBITION: AN IRRDC REPORT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i64, https://doi.org/10.1093/neuonc/noad073.245
MDB-13. CURRENT STATUS OF DIAGNOSIS AND TREATMENT FOR HIGH-RISK STAGE M2/M3 NON-WNT SUBTYPES MEDULLOBLASTOMA IN SOUTH CHINA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i64, https://doi.org/10.1093/neuonc/noad073.246
MDB-14. MULTI-OMICS OF HUMAN MEDULLOBLASTOMAS AND GENETIC LINEAGE TRACING IN VIVO IDENTIFY REGULATORS OF STEM-CELL MAINTENANCE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i64, https://doi.org/10.1093/neuonc/noad073.247
MDB-15. CLINICAL CHARACTERISTICS AND OUTCOME OF CHILDHOOD LI-FRAUMENI SYNDROME MEDULLOBLASTOMA PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i64–i65, https://doi.org/10.1093/neuonc/noad073.248
MDB-16. TARGETING EPIGENETIC DYSREGULATION IN PAEDIATRIC BRAIN TUMOURS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i65, https://doi.org/10.1093/neuonc/noad073.249
MDB-17. THE PTBP2 SPLICING FACTOR IS ESSENTIAL IN GROUP 3/4 MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i65, https://doi.org/10.1093/neuonc/noad073.250
MDB-18. MOLECULARLY-DEFINED MEDULLOBLASTOMA: POPULATION-LEVEL PATTERNS IN THE UNITED STATES, 2018-2019
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i65–i66, https://doi.org/10.1093/neuonc/noad073.251
MDB-19. MULTIOMIC PROFILING OF MEDULLOBLASTOMA REVEALS SUBTYPE-SPECIFIC TARGETABLE ALTERATIONS AT THE PROTEOME AND N-GLYCAN LEVEL
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i66, https://doi.org/10.1093/neuonc/noad073.252
MDB-20. IMPROVING THE PERSISTENCE OF CAR T CELLS AGAINST GROUP 3 MEDULLOBLASTOMAS VIA EPIGENETIC REGULATION OF EXHAUSTION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i66, https://doi.org/10.1093/neuonc/noad073.253
MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i66–i67, https://doi.org/10.1093/neuonc/noad073.254
MDB-23. ELP1 GERMLINE DEFICIENCY SENSITIZES THE GRANULE NEURON LINEAGE TO SHH MEDULLOBLASTOMA AND EXPOSES NOVEL THERAPEUTIC VULNERABILITIES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i67, https://doi.org/10.1093/neuonc/noad073.255
MDB-24. A DATA-DRIVEN APPROACH FOR THE IDENTIFICATION OF NEW SYNERGISTIC DRUG COMBINATIONS AGAINST NEURAL CANCERS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i67, https://doi.org/10.1093/neuonc/noad073.256
MDB-25. LARGE CELL/ANAPLASTIC MEDULLOBLASTOMA REPRESENTS MORE THAN ONE DISEASE ENTITY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i67, https://doi.org/10.1093/neuonc/noad073.257
MDB-26. CDK8 IS AN ONCOGENE IN GROUP 3 MEDULLOBLASTOMA THAT IMPACTS PROTEIN TRANSLATION BY REGULATING THE TRANSCRIPTIONAL ACTIVITY OF RIBOSOMAL GENES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i67–i68, https://doi.org/10.1093/neuonc/noad073.258
MDB-27. A PRO-DRUG OF TRIPTOLIDE IN CLINICAL DEVELOPMENT ATTENUATES HIGH-RISK MEDULLOBLASTOMA GROWTH
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i68, https://doi.org/10.1093/neuonc/noad073.259
MDB-28. DEEP LEARNING-BASED PERSONALIZED SURVIVAL PREDICTION FOR MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i68, https://doi.org/10.1093/neuonc/noad073.260
MDB-29. MEDULLOBLASTOMA SUBGROUP-SPECIFIC CHROMATIN STATES REVEAL NOVEL THERAPEUTIC VULNERABILITIES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i68, https://doi.org/10.1093/neuonc/noad073.261
MDB-30. IDENTIFICATION AND CHARACTERIZATION OF NOVEL TRANSCRIBED ULTRACONSERVED REGIONS AS LONG NON-CODING RNAS IN MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i68, https://doi.org/10.1093/neuonc/noad073.262
MDB-31. PRELIMINARY STUDY ON BIOLOGICAL SIGNIFICANCE OF WTX G435D MUTATION IN MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i68–i69, https://doi.org/10.1093/neuonc/noad073.263
MDB-32. TRANSLATION OF NON-CANONICAL OPEN READING FRAMES AS A CANCER CELL SURVIVAL MECHANISM IN CHILDHOOD MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i69, https://doi.org/10.1093/neuonc/noad073.264
MDB-33. REST AND USP37 CONTROL THE MTORC1-AUTOPHAGY AXIS IN MEDULLOBLASTOMA BY REGULATING RAPTOR DEGRADATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i69, https://doi.org/10.1093/neuonc/noad073.265
MDB-34. “INDUCING IRON IMBALANCE BY TARGETING THE ABCB7/GPX4 AXIS ACCELERATES FERROPTOSIS IN MEDULLOBLASTOMA”
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i69, https://doi.org/10.1093/neuonc/noad073.266
MDB-35. RECURRENT MEDULLOBLASTOMA A RARE COMPLETE RESPONSE IN EXTRA NEURAL DISEASE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i69–i70, https://doi.org/10.1093/neuonc/noad073.267
MDB-36. SONIDEGIB, GANT61, AND VELIPARIB TREATMENT BOTH ALONE AND IN COMBINATION INCREASES RADIATION SENSITIVITY IN PEDIATRIC SONIC HEDGEHOG MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i70, https://doi.org/10.1093/neuonc/noad073.268
MDB-37. CDK9 IS A DRUGGABLE MEDIATOR SUSTAINING MYC-DRIVEN TRANSCRIPTIONAL CIRCUITRY IN MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i70, https://doi.org/10.1093/neuonc/noad073.269
MDB-38. COMPUTATIONAL DRUG SENSITIVITY PREDICTS MEDULLOBLASTOMA SUBGROUP-SPECIFIC THERAPEUTICS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i70, https://doi.org/10.1093/neuonc/noad073.270
MDB-39. ASSESSMENT OF MEDULLOBLASTOMA PATIENTS THROUGH MONITORING EXTRACELLULAR VESICLES VIA SURFACE-ENHANCED RAMAN SPECTROSCOPY COMBINED WITH MACHINE LEARNING
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i70, https://doi.org/10.1093/neuonc/noad073.271
MDB-40. TRANSCRIPTOME-BASED DRUG REPURPOSING IN GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i70–i71, https://doi.org/10.1093/neuonc/noad073.272
MDB-41. TARGETING EPIGENETIC REGULATORS TO INHIBIT GROUP 3 MEDULLOBLASTOMA MIGRATION
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i71, https://doi.org/10.1093/neuonc/noad073.273
MDB-42. UNCOVERING DYNAMIC CHANGES IN MEDULLOBLASTOMA ASSOCIATED VASCULATURE IN ZEBRAFISH
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i71, https://doi.org/10.1093/neuonc/noad073.274
MDB-43. GRADIENT ENTROPY-BASED RADIOMIC RISK-SCORE FROM T1-WEIGHTED PRE-TREATMENT MRI SCANS CAN PREDICT SURVIVAL IN PEDIATRIC MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i71, https://doi.org/10.1093/neuonc/noad073.275
MDB-44. A TRANSFER LEARNING APPROACH FOR AUTOMATIC SEGMENTATION OF TUMOR SUB-COMPARTMENTS AND TUMOR HABITAT IN PEDIATRIC MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i71–i72, https://doi.org/10.1093/neuonc/noad073.276
MDB-45. SELECTIVE B7-H3 INHIBITORS NI1 AND NI4 REDUCE AGGRESSIVENESS OF GROUP 3 MEDULLOBLASTOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i72, https://doi.org/10.1093/neuonc/noad073.277
FINAL CATEGORY: NEUROSURGERY/FOCUSED ULTRASOUND/DRUG DELIVERY - SURG
SURG-02. MAGNETIC RESONANCE-GUIDED HIGH-INTENSITY FOCUSED ULTRASOUND (MRGHIFU) FOR TREATMENT OF LOW GRADE GLIOMA IN A PEDIATRIC PATIENT
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i72, https://doi.org/10.1093/neuonc/noad073.278
SURG-03. LAYER-BY-LAYER CORE-SHELL NANOPARTICLES FOR THE DELIVERY OF HDAC INHIBITORS TO THE CENTRAL NERVOUS SYSTEM
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i72, https://doi.org/10.1093/neuonc/noad073.279
SURG-04. INFLUENCE OF LOW-INTENSITY FOCUSED ULTRASOUND ON LOCOREGIONAL DRUG DELIVERY TO THE BRAIN
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i72–i73, https://doi.org/10.1093/neuonc/noad073.280
SURG-05. MRI-GUIDED FOCUSED ULTRASOUND BLOOD-BRAIN BARRIER DISRUPTION INCREASES DRUG DELIVERY AND EFFICACY IN AN ORTHOTOPIC DIPG MODEL
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i73, https://doi.org/10.1093/neuonc/noad073.281
SURG-06. ENHANCED DELIVERY OF ANTI-PD1 FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA USING FOCUSED ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER OPENING
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i73, https://doi.org/10.1093/neuonc/noad073.282
FINAL CATEGORY: OTHER (NOT FITTING IN ANY OTHER CATEGORY) - OTHR
OTHR-01. SUCCESSFUL DEVELOPMENT OF A LOCAL-REGIONAL POST-MORTEM BRAIN TUMOR DONATION PROGRAM
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i73, https://doi.org/10.1093/neuonc/noad073.283
OTHR-02. CHIMERIC AURORA A KINASE (AURKA) DEGRADERS EFFICIENTLY TARGET N-MYC
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i73–i74, https://doi.org/10.1093/neuonc/noad073.284
OTHR-03. CLASSIFICATION OF BRAIN TUMORS BY NANOPORE SEQUENCING OF CELL-FREE DNA FROM CEREBROSPINAL FLUID
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i74, https://doi.org/10.1093/neuonc/noad073.285
OTHR-04. DEVELOPMENT OF A FUNCTIONAL PLATFORM FOR REAL-TIME PERSONALIZED DRUG SENSITIVITY PROFILING OF PATIENT-DERIVED 3D FRESH TUMOR TISSUE CULTURES IN THE PEDIATRIC PRECISION ONCOLOGY PROGRAM INFORM
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i74–i75, https://doi.org/10.1093/neuonc/noad073.286
OTHR-05. A LIVING EX VIVO PLATFORM FOR FUNCTIONAL, PERSONALIZED PEDIATRIC BRAIN CANCER DIAGNOSIS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i75, https://doi.org/10.1093/neuonc/noad073.287
OTHR-06. NARRATIVE MEDICINE AND THE PRACTICE OF PEDIATRIC NEURO-ONCOLOGY: GRAPPLING WITH THE UNTHINKABLE
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i75, https://doi.org/10.1093/neuonc/noad073.288
OTHR-07. CIRCULATING MIRNAS AS A NON-INVASIVE MONITORING TOOL FOR PEDIATRIC BRAIN TUMORS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i75, https://doi.org/10.1093/neuonc/noad073.289
OTHR-08. MULTIDISCIPLINARY APPROACH TO PAEDIATRIC BRAIN CANCER BIO-BANKING IMPROVES ENROLLMENT, FACILITATES DISCOVERY RESEARCH, AND ENABLES BETTER ACCESS TO DIAGNOSTIC AND THERAPEUTIC STUDIES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i75–i76, https://doi.org/10.1093/neuonc/noad073.290
OTHR-09. A RETROSPECTIVE COHORT STUDY EXAMINING RADIOLOGIC AND CLINICAL CHARACTERISTICS OF CHILDREN AND ADOLESCENTS WITH ATYPICAL/COMPLEX PINEAL CYSTS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i76, https://doi.org/10.1093/neuonc/noad073.291
OTHR-10. COLLABORATIVE EFFORTS FOR HOSPITAL-BASED BIOBANK DEVELOPMENT AND OPTIMIZATION TO ENSURE QUALITY PEDIATRIC SPECIMENS FOR TRANSLATIONAL RESEARCH
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i76, https://doi.org/10.1093/neuonc/noad073.292
OTHR-11. THE IMPORTANCE AND INFLUENCE OF PATIENT FAMILY INVOLVEMENT IN PEDIATRIC NEURO-ONCOLOGY RESEARCH
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i76, https://doi.org/10.1093/neuonc/noad073.293
OTHR-12. LOCATION-RELEVANT GROWTH FACTOR DEPENDENCE ON THE FORMATION OF PEDIATRIC BRAIN TUMOR ORGANOIDS FROM PDOX MODELS AND PATIENT SAMPLES
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i76–i77, https://doi.org/10.1093/neuonc/noad073.294
OTHR-13. IDENTIFYING INDIVIDUALS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS AT RISK FOR HEREDITARY CANCER SYNDROMES USING A STATEWIDE CANCER REGISTRY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i77, https://doi.org/10.1093/neuonc/noad073.295
OTHR-14. PROFILE & OUTCOME OF BRAIN TUMORS IN THE YOUNG CHILDREN < 3YEARS OF AGE: EXPERIENCE FROM A TERTIARY CANCER CENTER IN INDIA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i77, https://doi.org/10.1093/neuonc/noad073.296
FINAL CATEGORY: RADIATION ONCOLOGY - XRT
XRT-01. LONG-TERM HEARING LOSS IN CHILDREN WITH MEDULLOBLASTOMA AFTER PROTON IRRADIATION AND CHEMOTHERAPY
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i77, https://doi.org/10.1093/neuonc/noad073.297
XRT-02. SINGLE-CELL RNA SEQUENCING IDENTIFIES FUNCTIONAL MACROPHAGE SUBSETS THAT ARE ENRICHED IN RESPONSE TO DIFFERENTIAL PHAGOCYTOSIS INDUCTION AGAINST GLIOMA
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i77, https://doi.org/10.1093/neuonc/noad073.298
XRT-03. EFFICACY OF RE-IRRADIATION FOR PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMAS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Pages i77–i78, https://doi.org/10.1093/neuonc/noad073.299
XRT-04. THE ROLE OF STEREOTACTIC RADIOSURGERY FOR MENINGIOMAS IN PEDIATRIC PATIENTS
Neuro-Oncology, Volume 25, Issue Supplement_1, June 2023, Page i78, https://doi.org/10.1093/neuonc/noad073.300
